Regulation of cellular therapy in Australia

Pathology

Volumn 43, Issue 6, 2011, Pages 627-634

  Trickett, Annette E ^a,b   Wallz, Dominic M ^c,d  

^a Agency for Clinical Innovation   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Accreditation; Biologicals regulation; Cell therapy; GMP

Indexed keywords

EID: 83055163841     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32834b3cfa     Document Type: Article

References (37)

1. Scott C. Australia. Bio Process Int 2011; 9 (S6): 4-7.
2. KPMG. Competitive Alternatives: KPMG's Guide to International Business Location. Toronto: KPMG, 2010.
3. Baume P. A Question of Balance: Report on the Future of Drug Evaluation in Australia. Canberra: Australian Government Publishing Service, 1991.
4. Rankin J, Mason J, Kottege N, Andersson NY Clinical trials of unapproved medicines in Australia. Med J Aust 2006; 185: 342-3. (Pubitemid 44515443)
5. Gratwohl A, Baldomero H, Schwendener A, et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009; 43: 275-91.
6. Prockop DJ, Brenner M, Fibbe WE, et al. Defining the risks of mesench-ymal stromal cell therapy. Cytotherapy 2010; 12: 576-8.
7. US National Institutes of Health (NIH). Clinical Trials.gov. July 2011 (cited July 2011). http://clinicaltrials.gov
8. Buckler RL. Opportunities in regenerative medicine. Bio Process Int 2011; 9: 14-9.
9. Ljungman P, Bregni M, Brune M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219-34.
10. Wall DM, Prince HM. Regulation of cellular therapies: the Australian perspective. Cytotherapy 2003; 5: 284-8. (Pubitemid 37264994)
11. Therapeutic Goods Administration. Therapeutic Goods (Excluded Goods) Order No. 1 of2011. Commonwealth of Australia Gazette 2011; 31 May: S91.http://www.tga.gov.au/industry/legislation-excluded-goods-order-1101. htm
12. Snyder EY. The risk of putting something where it does not belong: mesenchymal stem cells produce masses in the brain. Exp Neurol 2011; 230: 75-7.
13. Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med 2006; 355: 1730-5. (Pubitemid 44583964)
14. Gillard J. Landmark agreement to achieve world standards in therapeutic products. (Press release.) 21 June 2011 (cited July 2011). www.pm.gov. au/press-office/landmark-agreement-achieve-world-standards-therapeutic-products
15. Therapeutic Goods Administration. Australia's Regulatory Authority for Therapeutic Goods. July 2011 (cited July 2011). www.tga.gov.au
16. Therapeutic Goods Administration. Therapeutic Goods Act 1989. Therapeutic Goods (Things that are not Biologicals) Determination No. 1 of 2011. 31 May 2011 (cited July 2011). www.comlaw.gov.au/Details/ F2011L00894
17. Therapeutic Goods Administration. Clinical trial regulation in Australia. 1 June 2011 (cited July 2011). www.tga.gov.au/pdf/presentations/presenta-tion- omq-110526-clark.pdf
18. Therapeutic Goods Administration. Cost Recovery Impact Statement: Regulation Of Biologicals (Human Cell And Tissue Therapy Products), February2011. Canberra: Therapeutic Goods Administration, 2011. http:// www.tga.gov.au/pdf/fees-cris-biologicals-110201.pdf
19. Ellison C. New program for orphan drugs. (Press release). 10 April 1997 (cited July 2011). www.health.gov.au/internet/main/publishing.nsf/ Content/health-archive-mediarel-1997-ceorphan.htm
20. Therapeutic Goods Administration. Therapeutic Goods Act 1989. Ther-apeutic Goods Order No. 75: Standard For Haematopoietic Progenitor Cells Derived From Cord Blood. 1 August 2007 (cited July 2011). www.tga. gov.au/docs/html/tgo/tgo75.htm
21. Therapeutic Goods Administration. Current standards applicable to TGA-licensed HPC manufacturers. 24 September 2009 (cited July 2011). http:// www.tga.gov.au/industry/manuf-btb-hpc-standards.htm
22. Hurley CK, Foeken L, Horowitz M, Lindberg B, McGregor M, Sacchi N. Standards, regulations and accreditation for registries involved in the worldwide exchange of hematopoietic stem cell donors and products. Bone Marrow Transplant 2010; 45: 819-24.
23. Foundation for the Accreditation of Cellular Pathology (FACT). July 2011 (cited July 2011). www.factwebsite.org
24. Joint Accreditation Committee ISCT EBMT. July 2011 (cited July 2011). www.jacie.org
25. To LB, Shepherd KM, Lam-Po-Tang R, Szer J, McGrath KM. Guidelines for the collection, processing, storage and of administration ofhemopoietic stem and progenitor cells for transplantation. Report of the Working Party on Hemopoietic Stem Cell Processing, Hematology Discipline Advisory Committee, the Royal College of Pathologists of Australasia. Pathology 1998; 30: 276-85
26. National Pathology Accreditation Advisory Council (NPAAC). Requirements for Procedures Related to the Collection, Processing, Storage and Issue of Human Haemopoietic Progenitor Cells (Third Edition 2009). Canberra: Australian Government Department of Health and Age-ing, 2009. www.health.gov.au/internet/ main/publishing.nsf/Content/health-npaac-docs-human-haemopoietic.htm
27. Wall DA. Regulatory issues in cord blood banking and transplantation. Best Pract Res Clin Haematol 2010; 23: 171-7.
28. Bone Marrow Donors Worldwide (BMDW). July 2011 (cited July 2011). www.bmdw.org
29. World Marrow Donor Association (WMDA). 13 July 2011 (cited July 2011). www.worldmarrow.org
30. Alliance for Harmonisation of Cellular Therapy Accreditation (AHCTA). July 2011 (cited July 2011). www.ahcta.org
31. Zahnd D, Leibundgut K, Zenhausern R, et al. Implementation of the JACIE standards for a haematopoietic progenitor cell transplantation programme: a cost analysis. Bone Marrow Transplant 2004; 34: 847-53. (Pubitemid 39562135)
32. Pamphilon D, Apperley JF, Samson D, Slaper-Cortenbach I, McGrath E. JACIE accreditation in 2008: demonstrating excellence in stem cell transplantation. Hematol Oncol Stem Cell Ther 2009; 2: 311-9.
33. Apperley J. Just another cost increasing exercise (JACIE)? Bone Marrow Transplant 2004; 34: 835-8. (Pubitemid 39562133)
34. Gratwohl A, Brand R, Niederwieser D, et al. Introduction of a quality management system and outcome after hematopoietic stem-cell transplan-tation. J Clin Oncol 2011; 29: 1980-6.
35. Nivison-Smith I, Simpson JM, Dodds AJ, Ma DD, Szer J, Bradstock KF. Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates. Biol Blood Marrow Transplant 2009; 15: 1323-30.
36. Moore AS, Shaw PJ, Hallahan AR, et al. Haemopoietic stem cell Transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. Med J Aust 2009; 190: 121-5.
37. Stanevsky A, Goldstein G, Nagler A. Umbilical cord blood transplantation: pros, cons and beyond. Blood Rev 2009; 23: 199-204.